SUMMARY A cross sectional study was carried out in children receiving treatment for acute lymphoblastic leukaemia to determine the prevalence of trimethoprim resistant organisms in their gut flora and to compare this with a control population. There was a significantly higher prevalence of trimethoprim resistant bacteria in the study group (61%) compared with controls (14%). A longitudinal study showed that emergence of these organisms was intermittent during treatment.
Children receiving chemotherapy for acute lymphoblastic leukaemia are at increased risk of infection by Pneumocystis carinii. A combination of trimethoprim and sulphamethoxazole, co-trimoxazole, has proved useful in preventing such infecions' and is now included in the treatment protocol for acute lymphoblastic leukaemia. Co Colonies growing on the selective plate were identified using standard techniques and their susceptibility to a series of antibiotics was determined using a controlled disc diffusion method.8 Minimum inhibitory concentrations were determined using an agar incorporation method, as described previously. 9 The survey was designed in two parts.
Firstly, a cross sectional survey was carried out to determine the prevalence of trimethoprim resistant aerobes in the intestinal flora of all children receiving chemotherapy for acute lymphoblastic leukaemia. Specimens were collected over two weeks when children were attending as outpatients. This was compared with the prevalence of carriage of trimethoprim resistant bacteria in the faeces of 568 children who were not receiving co-trimoxazole.
Secondly, a longitudinal study was carried out on children presenting with acute lymphoblastic leukaemia for the first time. Specimens were obtained before induction and at the beginning of prophylaxis and thereafter at monthly intervals. Three patients received co-trimoxazole daily and the remaining patients thrice weekly, at dosages of trimethoprim 160 mg/m2/day and sulphamethoxazole 800 mg/m2/day.
Statistical analyses were performed using x2 test with Yates's correction for small numbers where applicable.
Results
In the prevalence study trimethoprim resistant bacteria were not isolated from the anterior nares or throats of any children, nor were trimethoprim resistant Gram positive bacteria isolated from any site. Of 41 children who received prophylaxis with co-trimoxazole, 25 (61%) were excreting trimethoprim resistant bacteria in their faeces. In contrast, significantly fewer (p<0001) of the control children (79 of 568, (14%)) were excreting trimethoprim resistant bacteria. All isolates obtained were Gram negative. A greater variety of trimethoprim resistant bacteria were obtained from the control group, but Escherichia coli was the predominant isolate in both groups (Table 1 ). All the resistant bacteria had minimal inhibitory concentrations of greater than 800 mg/l trimethoprim. Twenty four (96%) of the trimethoprim resistant bacteria specimens isolated from the study group were also resistant to sulphamethoxazole, whereas 65 (82%) of those obtained from the control group were similarly resistant. None of the isolates obtained from the study group was resistant to gentamicin or tobramycin, but 22 (88%) were resistant to streptomycin and spectinomycin. Twenty three (92%) of the trimethoprim resistant bacteria from the study group were also resistant to ampicillin and ticarcillin and 77 (97%) of those from the control group were similarly resistant.
Thirteen children were entered into the longitudinal study. Two of the children (15%) were already excreting trimethoprim resistant strains of E. coli before they received chemotherapy (Table 2) . They both continued, intermittently, to excrete trimethoprim resistant E. coli of the same biotype as the original isolates. One child also excreted a trimethoprim resistant strain of serratia on a single occasion. Seven patients (54%) who were surveyed for a total of 22 months did not acquire trimethoprim resistant bacteria. Five of these patients were followed up for only one to two months. Of the four patients (36%) who acquired resistant bacteria, only one had acquired them by the second month, two by the third month, and one by the fourth month. Once colonisation had occurred, it did not follow that the patient continued to be colonised; indeed, intermittent excretion of resistant bacteria was the rule. There was no difference in risk of acquisition of resistant bacteria between children receiving daily or thrice weekly co-trimoxazole.
Discussion
Sulphamethoxazole and trimethoprim inhibit two enzymes necessary for bacterial synthesis of folic In children with leukaemia co-trimoxazole is given prophylactically in an attempt to prevent Ps. carinii infections. During the study no child became infected. There is no doubt, however, that the use of co-trimoxazole in our patients selected for trimethoprim resistant bacteria. Sixty one per cent of those who received prophylaxis with cotrimoxazole were found to be excreting trimethoprim resistant bacteria, mainly E. coli, whereas only 14% of children who did not receive prophylaxis with co-trimoxazole were excreting such bacteria. Co-trimoxazole also apparently coselected for resistance to sulphonamides as 96% of the trimethoprim resistant bacteria isolated from the children with leukaemia were resistant compared with 82% of the control population. Most isolates from both groups were resistant to ampicillin and ticarcillin, but there was no evidence of resistance to gentamicin or tobramycin. The fact that 88% of the trimethoprim resistant bacteria were also resistant to streptomycin and spectinomycin may provide an insight into the genetics of this resistance as genes for resistance to trimethoprim, streptomycin, and spectinomycin are located on a single transposon (Tn7).12
No patient became infected with trimethoprim resistant bacteria during treatment with cotrimoxazole. It is noteworthy that trimethoprim resistant Gram positive bacteria were not selected by this prophylactic regimen as 70% of episodes of bacteraemia in our patients with leukaemia are due to Gram positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae (unpublished data). In the longitudinal study 15% of patients were already colonised by trimethoprim resistant coliforms before treatment, which is in close agreement with the prevalence of resistance in the control population. Colonisation did not occur until the second month of prophylaxis and in most patients was intermittent.
As it is necessary to include prophylaxis for pneumocystis infection it is fortunate that although co-trimoxazole selects for resistant coliforms in the gastrointestinal tract, such bacteria, to date, have rarely caused serious infection. It would also seem that co-trimoxazole has not yet selected for plasmids that encode resistance to many different antimicrobials and, in particular, to gentamicin or tobramycin. Regimens for treatment of acute lymphoblastic leukaemia, however, have become increasingly intensive, with a high incidence of profound neutropenia and increased side effects from chemotherapy. This, in particular, gives increased potential for invasive infections of gut origin and remains so throughout continuing treatment. 13 Vigilance is therefore necessary with regard to the increased prevalence of trimethoprim resistant bacteria in the gastrointestinal tract of children with leukaemia and the potential for selecting resistance to many commonly used antimicrobials. 
